^
Association details:
Biomarker:MAP2K2 N126D
Cancer:Melanoma
Drug:Mekinist (trametinib) (MEK inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

Excerpt:
The MEK2V35M, MEK2L46F, and MEK2N126D mutants also engendered resistance to RAF and MEK inhibition, although their effect were not as pronounced as those of MEK2C125S.
DOI:
10.1158/2159-8290.CD-13-0617